Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $166.1538.

Several brokerages have recently weighed in on RGEN. UBS Group decreased their target price on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. HC Wainwright lifted their target price on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Royal Bank Of Canada began coverage on shares of Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price on the stock. Finally, Roth Mkm began coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock.

Repligen Stock Performance

NASDAQ RGEN opened at $115.19 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The firm has a market capitalization of $6.50 billion, a price-to-earnings ratio of 127.99, a P/E/G ratio of 2.22 and a beta of 1.09. The company’s fifty day moving average is $117.78 and its two-hundred day moving average is $140.26. Repligen has a 52-week low of $100.99 and a 52-week high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The company had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts forecast that Repligen will post 1.99 EPS for the current year.

Institutional Trading of Repligen

Institutional investors have recently made changes to their positions in the business. Bayforest Capital Ltd acquired a new stake in shares of Repligen during the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen during the 4th quarter valued at about $33,000. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the third quarter valued at about $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen in the fourth quarter valued at about $36,000. Finally, Farther Finance Advisors LLC boosted its position in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.